Information Provided By:
Fly News Breaks for November 26, 2019
Nov 26, 2019 | 07:09 EDT
H.C. Wainwright analyst Edward White downgraded La Jolla Pharmaceutical to Neutral from Buy without a price target. The analyst cites the discontinuation of the company's pipeline product LJPC-401 and the "sudden departure" of its CEO for the downgrade. White says he's "not comfortable" at this point to determine a price target given the perceived lack of clarity at La Jolla.
News For LJPC From the Last 2 Days
There are no results for your query LJPC